



ASX Announcement

Quarterly Activities Report and Appendix 4C For the quarter ending March 2026

Sydney, Australia – 24 April 2026 – [BrainChip Holdings Ltd](#) (ASX: **BRN**, OTCQX: **BRCHF**, **BCHPY**) (“BrainChip”), the world’s first commercial producer of neuromorphic artificial intelligence technology, today provides the Quarterly Activities Report in conjunction with its Appendix 4C lodged for the quarter ending 31 March 2026.

Key Highlights

- Customer cash inflows of US\$0.7M, improved from the prior quarter (US\$0.4M).
- Payments to suppliers and employees of US\$4.3M, consistent with the prior quarter (US\$4.3M).
- Executed multiple strategic licensing and collaboration agreements, expanding commercial adoption of Akida™ (“Akida”) neuromorphic IP.
- Entered into a global Akida 2.0 licensing agreement with EDGEAI, establishing a new royalty-bearing customer relationship.
- Selected by ForwardEdge ASIC, a Lockheed Martin subsidiary, as the neuromorphic AI provider for future custom ASIC platforms.
- Initiated the AKD2500 next-generation custom silicon development program aligned with the Akida 2.0 roadmap.
- Launched new reference platforms and evaluation capabilities, including AkidaTag© (“AkidaTag”) and cloud-based Akida Pico access.
- Expanded defence, industrial and education engagement through strategic partnerships and sponsorship activities.
- Reaffirmed prior ASX announcement regarding production availability of the AKD1500 neuromorphic processor, targeted for Q3 CY2026.

Overview

During the first quarter ended 31 March 2026, BrainChip continued to advance its strategy to commercialise ultra-low power neuromorphic edge AI. The Company focused on technology execution, customer engagement and ecosystem expansion, with multiple product announcements

For personal use only

and strategic collaborations reinforcing Akida as a differentiated solution for defence, industrial, wearable and IoT applications.

Technology and Product Development

AKD1500 Production Update

The Company confirms that the AKD1500 neuromorphic processor, BrainChip's first high-volume production silicon device, remains on track for production availability in the third quarter of calendar year 2026. The Company anticipates receiving approximately 70,000 units in this first production run. Deliveries will begin in July of 2026 and span a 4–6-week period. This timing is consistent with details provided in earlier ASX announcements. AKD1500 is designed as a dedicated neuromorphic AI co-processor optimised for ultra-low power, always-on inference in edge systems, with target applications across defence, industrial sensing, robotics and embedded IoT markets. Customer evaluation programs and platform integrations continue in parallel with final production preparations. The Company will place subsequent orders on an as-needed basis and anticipates delivery within four months of the start of production.

In February 2026, BrainChip initiated the AKD2500 next-generation custom silicon development program, a material milestone in the Akida 2.0 roadmap. The AKD2500 device will be implemented on Taiwan Semiconductor's 12-nanometre process technology, enabling customers to evaluate next-generation neuromorphic performance on a widely adopted manufacturing node. The project is structured as a staged pilot development program with an expected prototype silicon tape-out in the second half of calendar 2026. The total anticipated cost for the project is approximately US\$2.5 million, incurred progressively against defined technical milestones.

The Company also announced the immediate availability of Akida Pico via FPGA cloud access, allowing customers to remotely evaluate Akida IP without the need for physical development hardware. This capability is expected to accelerate early engagement, proof-of-concept development and design-win conversion across multiple end markets.

At Embedded World 2026, BrainChip announced the AkidaTag reference platform for always-on wearable and battery-powered sensing applications. AkidaTag combines the AKD1500 neuromorphic co-processor with Nordic Semiconductor connectivity to deliver on-device learning, personalisation and inference without cloud dependence. Target use cases include health monitoring, industrial condition monitoring, voice activation, and acoustic classification.

Commercial Update

EDGEAI Akida 2.0 Licensing Agreement

On 30 March 2026, BrainChip entered into a global, non-exclusive technology licensing agreement with EDGEAI, a Korea-based semiconductor company focused on high-efficiency AI processors for

edge and endpoint devices. Under the agreement, EDGEAI is licensed to integrate Akida 2.0 neuromorphic IP into its forthcoming system-on-chip products, supported by BrainChip's development tools, documentation and engineering services. Commercial terms include milestone-based payments associated with IP delivery and integration services, together with ongoing royalties linked to sales of EDGEAI products incorporating Akida technology. The agreement further validates the commercial relevance of BrainChip's neuromorphic architecture and supports the Company's recurring, high-margin royalty model.

ForwardEdge ASIC Strategic Engagement

In March 2026, BrainChip was selected by ForwardEdge ASIC, a wholly owned subsidiary of Lockheed Martin, as the neuromorphic AI technology provider for future ASIC platforms. This strategic collaboration is focused on embedding BrainChip's Akida architecture directly into advanced custom silicon solutions for aerospace, defence, radio frequency and signal-processing applications. By integrating neuromorphic AI acceleration with radio frequency and signal-processing chains, the collaboration aims to enable cognitive sensing and real-time decision-making at the edge, with reduced latency, lower power consumption and minimal data movement. Management views this engagement as a significant validation of Akida's suitability for mission-critical environments where size, weight, and power use are tightly constrained.

During the quarter, BrainChip also announced Neuromorphyx™ as a strategic customer and go-to-market partner for the AKD1500 processor. Neuromorphyx plans to integrate AKD1500 into its modular Vision NeuroNode™ architecture to support ruggedised, always-on edge intelligence for defence, robotics and industrial sensing deployments.

Key Sponsorship

In February 2026, BrainChip was named the Official Technology Sponsor for Raytheon's 2025-2026 Autonomous Vehicle Competition, 'Operation Touchdown'. As part of the sponsorship, BrainChip supplied AKD1000 neuromorphic processors, engineering support and development resources to participating university teams.

Outlook

Subsequent to the end of the quarter, BrainChip received an initial order from Onsor Technologies for AKD1500 neuromorphic processors. The order relates to Onsor's development of AI-enabled smart glasses designed to assist in the prediction of epileptic seizures through continuous, on-device sensing and inference. The AKD1500 processors will be used as dedicated neuromorphic AI co-processors within Onsor's wearable platform, supporting ultra-low power, always-on operation in a form factor suitable for daily use. While the order was modest, when combined with committed orders from Parsons and Nex-Novus it reflects progressing customer engagement ahead of broader AKD1500 production availability.

BrainChip concluded the March 2026 quarter with continued momentum across technology development, licensing activity, and strategic customer engagement. The Company remains focused on advancing its Akida 2.0 roadmap, expanding design-win opportunities and converting partnerships into long-term royalty and product revenue streams.

Financial Update

The Company ended the March Quarter with US\$25.3M in cash compared to US\$31.7M in the prior quarter.

BrainChip reported net operating cash outflows of US\$5.3M, an increase from US\$3.5M in the prior quarter. Net operating cash outflows comprise:

- Cash inflows from customers in the current quarter of US\$0.7M were improved from the prior quarter (US\$0.4M) with deposits paid by new customers.
- Payments to suppliers and employees were US\$4.3M, which is consistent with the prior quarter (US\$4.3M).
- The prior quarter included US\$0.3M of R&D tax incentives received.

Cash used for operating activities includes payments to BrainChip's Board of Directors totaling US\$222,147 as noted in item 6.1 of the accompanying Appendix 4C, comprising fees for Non-Executive Directors and salaries for Executive Directors.

Investment cash outflows of US\$1.25M related to capitalised R&D associated with production of the AKD1500.

Authorisation

This announcement has been authorised for release by the Board of Directors of BrainChip Holdings Ltd.

About BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY)

BrainChip is the worldwide leader in Edge AI on-chip processing and learning. The company's first-to-market, fully digital, event-based AI processor, Akida™, uses neuromorphic principles to mimic the human brain, analysing only essential sensor inputs at the point of acquisition and processing data with unmatched efficiency, precision, and energy economy. BrainChip's Temporal Event-based Neural Networks (TENNs) build on State-Space Models (SSMs), deliver time-aware, event-driven intelligence optimized for scalable, real-time streaming applications. These innovations

make low-power Edge AI deployable across industries such as aerospace, autonomous vehicles, robotics, industrial IoT, consumer devices, and wearables. BrainChip is advancing the future of intelligent computing, bringing AI closer to the sensor and closer to real-time.

Explore more at www.brainchip.com.

Follow BrainChip:

Twitter: https://www.twitter.com/BrainChip_inc

LinkedIn: <https://www.linkedin.com/company/7792006>

Investor Contact

IR@brainchip.com

Media Contact:

Madeline Coe

Bospar

prforbrainchip@bospar.com

+1-224-433-9056

For personal use only

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

BrainChip Holdings Ltd

ABN

64 151 159 812

Quarter ended ("current quarter")

31 March 2026

Consolidated statement of cash flows	Current quarter \$US'000	Year to date (3 months) \$US'000
1. Cash flows from operating activities		
1.1 Receipts from customers	664	664
1.2 Payments for		
(a) research and development	(2,759)	(2,759)
(b) product manufacturing and operating costs	(362)	(362)
(c) advertising and marketing	(1,303)	(1,303)
(d) leased assets	-	-
(e) staff costs	(896)	(896)
(f) administration and corporate costs	(772)	(772)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	181	181
1.5 Interest and other costs of finance paid	(11)	(11)
1.6 Income taxes paid	(18)	(18)
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(5,276)	(5,276)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(18)	(18)

For personal use only

Consolidated statement of cash flows	Current quarter \$US'000	Year to date (3 months) \$US'000
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	(1,247)	(1,247)
2.2 Proceeds from disposal of:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	2	2
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	(1,263)	(1,263)

3. Cash flows from financing activities		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2 Proceeds from issue of convertible debt securities	-	-
3.3 Proceeds from exercise of options	12	12
3.4 Transaction costs related to issues of equity securities or convertible debt securities	(20)	(20)
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)		
- Reduction in leases	(110)	(110)
- Funds (paid to)/received from LTIP participants on sale of equity units.	-	-
3.10 Net cash from / (used in) financing activities	(118)	(118)

Consolidated statement of cash flows	Current quarter \$US'000	Year to date (3 months) \$US'000
---	-------------------------------------	---

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	31,712	31,712
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(5,276)	(5,276)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(1,263)	(1,263)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(118)	(118)
4.5	Effect of movement in exchange rates on cash held	269	269
4.6	Cash and cash equivalents at end of period	25,324	25,324

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$US'000	Previous quarter \$US'000
5.1	Bank balances	25,324	31,712
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	25,324	31,712

6.	Payments to related parties of the entity and their associates	Current quarter \$US'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	222
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7. Financing facilities	Total facility amount at quarter end \$US'000	Amount drawn at quarter end \$US'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	665	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	665	-
7.5 Unused financing facilities available at quarter end		665
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
BrainChip Inc has an Irrevocable Standby Letter of Credit to the value of US\$665,000 with JPMorgan Chase Bank as security for the office lease. The Letter of Credit expires 31 May 2027 and incurs interest at 0.9%.		

8. Estimated cash available for future operating activities	\$US'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(5,276)
8.2 Cash and cash equivalents at quarter end (item 4.6)	25,324
8.3 Unused finance facilities available at quarter end (item 7.5)	665
8.4 Total available funding (item 8.2 + item 8.3)	25,989
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	4.93
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: n/a	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: n/a	

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: n/a

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

24 April 2026

Date:

The Board of Directors

Authorised by:
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.